3Park SC, Jung SW, Lee JW, et al. The effects of toherodine ex- tended release and alfuzosin for the treatment of double -j stent - related symptoms[J]. J Endourol, 2009, 23(11) : 1913 -1917.
4Chrisofos M, Gkougkousis E, Skolarikos A, et al. Alfuzosin vs ta- msulosin in treating double - J sent related morbidity; a prospec- tive comparative study[J]. J Urol, 2007, 177 (4 suppl) : 544.
5Deliveliotis, C, Chrisofos M, Gougousis E, et al. Is there a role for alphal - blockers in treating double - J stent - related symp- toms?[J]. Urology, 2006, 67(1): 35 -39.
6Park CH, Chang HS, Oh BR, et al. Efficacy of low - dose tamsu- losin on lower urinay tract symptoms suggestive of benign prostatic hyperplasia[ J]. Clin Drug Invest, 2004, 24( 1 ) : 41 -47.
7Crawfbrd ED. Management of lower urinary tract symptoms sugges- tive of benign prostateic hyperplasia : the central role of the patient risk profile[J]. BJU Int, 2005, 95(suppl 4) : 1 -5.
8Joshi HB, Newns N, Stainthorpe A, et al. Ureteral stent symptom questionnaire: development and validation of a multidimensional quality of life measure[ J ]. J Urol, 2003, 169 (3) : 1060 -1064.
9A1 - Busaidy SS, Prem AR, Medhat M. Pediatric staghorn calcu- li: the role of extracorporeal shock wave lithotripsy monotherapy with special reference to ureteral stenting[ J]. J Urol, 2003, 169 (2) : 629 -633.
10Zhou S, Paz O, Cao JM, et al. Differential beta - adrenoceptor expression induced by nerve growth factor infusion into the canine right and left stellate ganglia[J]. Heart Rhythm, 2005, 2(12) : 1347 - 1355.
